Taiwan-based biopharmaceutical company PharmaEssentia Corp. is expanding its global manufacturing and commercial footprint, planning a US$46 million production facility in Puerto Rico to begin operations in 2027 while consolidating its North American business to support the international growth of its blood cancer drug ropeginterferon alfa-2b (Ropeg).Read More
Taiwan drugmaker PharmaEssentia plans US$46 million Puerto Rico plant as it expands global reach
